Clinical Trial Update: Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer [EARLY_Phase 1]

View source ↗

Summary

An early-phase pilot study of Glembatumumab Vedotin as neoadjuvant therapy for gp-NMB-expressing high-risk triple-negative breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Glembatumumab Vedotin (glembatumumab vedotin)

Snippet

Sponsor: University of Virginia | Conditions: Triple Negative Breast Cancer | EARLY_Phase 1 | Status: WITHDRAWN